Intercell and GSK form strategic alliance to develop and commercialize innovative needle-free patch-based vaccines
Under the terms of the agreement, GSK will make an up-front cash contribution of EUR 33.6 (USD 49.4) million, in addition to an equity investment of up to EUR 84 (USD 123.5) million through a staggered shareholding purchase option of up to 5 % in Intercell. Included in the agreement are Intercell's investigational TD vaccine, currently in Phase III, and an investigational single application pandemic influenza vaccine in Phase II, as well as other potential future patch vaccines.
GSK and Intercell will collaborate on the TD Vaccine Patch, currently in phase III, to commercialize this vaccine once it has gained regulatory approval. The agreement will also include a collaboration between the two companies to further develop and co-market an innovative pandemic influenza vaccination approach.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.